Tilray® Expands Leadership Team in Europe to Drive Global Expansion Strategy
NANAIMO, British Columbia--(BUSINESS WIRE)--Feb 7, 2019--Today, Tilray, Inc. (NASDAQ:TLRY), a global pioneer in cannabis production, research, cultivation and distribution, announces the expansion of its global senior leadership team with the appointment of Sascha Mielcarek as Managing Director, Europe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190207005166/en/
Sascha Mielcarek, Managing Director, Europe, Tilray (Photo: Business Wire)
Sascha Mielcarek comes to Tilray with over 18 years of experience in the pharmaceutical industry bringing extensive global commercial sales and marketing expertise in international markets such as the U.S., Europe and Latin America. Sascha most recently was at Grünenthal as Global Head of Gout Business Unit & Alliance Implementation Lead.
“The expansion of our European senior leadership team strengthens Tilray’s ability to enter into new addressable markets and solidify our presence in existing European markets,” says Brendan Kennedy, Tilray CEO. “Sascha brings an unmatched level of expertise from his years of experience in the European and global pharmaceutical industry and we’re very pleased to welcome him to our team.”
Tilray has a pioneering track-record as a company committed to making pharmaceutical-grade medical cannabis products available to patients in-need all over the world. With global operations currently located Australia & New Zealand, Canada, Germany, Latin America, and Portugal, Tilray is well-positioned to expand the availability of its branded cannabis products in other countries as regulations allow. Tilray has already successfully exported within Europe to: Czech Republic, Germany, United Kingdom, Cyprus and Croatia, and outside of Europe to, Argentina, Chile, United States, South Africa, Australia and New Zealand.
In the new role of Managing Director, Europe, Sascha will provide strategic leadership to Tilray’s existing European team as it pursues new market entries in Europe and continues to strengthen the company’s position in existing markets. Sascha and his team will be working collaboratively with Tilray’s team of experts at the state-of-the-art facility in Cantanhede, Portugal, which will act as the primary hub for the cultivation, processing, research and distribution of branded Tilray products throughout Europe, once fully licensed.
Sascha joins Tilray’s recent global senior leadership hires: Greg Christopher as EVP of Operations, Rita Seguin as EVP of Human Resources, Dara Redler as General Counsel and Charlie Cain as VP of Retail. Tilray looks forward to sharing more information about the expansion of its global leadership team and operations within Europe.
About Tilray® Tilray (NASDAQ:TLRY) is a global pioneer in the research, cultivation, production and distribution of cannabis and cannabinoids currently serving tens of thousands of patients and consumers in twelve countries spanning five continents.
Cautionary Note Regarding Forward-looking Statements This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of Canadian securities laws, or collectively, forward-looking statements. Forward-looking statements in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions and include statements relating to the global success of the Tilray. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment and future approvals and permits. Actual results, performance or achievement could differ materially from that expressed in, or implied by, any forward-looking statements in this press release, and, accordingly, you should not place undue reliance on any such forward-looking statements and they are not guarantees of future results. Forward-looking statements involve significant risks, assumptions, uncertainties and other factors that may cause actual future results or anticipated events to differ materially from those expressed or implied in any forward-looking statements. Please see the heading “Risk Factors” in Tilray’s Quarterly Report on Form 10-Q, which was filed with the Securities and Exchange Commission and Canadian securities regulators on November 14, 2018, for a discussion of the material risk factors that could cause actual results to differ materially from the forward-looking information. Tilray does not undertake to update any forward-looking statements that are included herein, except in accordance with applicable securities laws.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190207005166/en/
Media: Chrissy Roebuck, 1-833-206-8161,email@example.com Investors: Katie Turner, +1-646-277-1228, Katie.firstname.lastname@example.org
KEYWORD: EUROPE NORTH AMERICA CANADA FRANCE GERMANY
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL PROFESSIONAL SERVICES HUMAN RESOURCES
SOURCE: Tilray, Inc.
Copyright Business Wire 2019.
PUB: 02/07/2019 03:00 AM/DISC: 02/07/2019 03:01 AM